Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5813263 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1NPSR1HSD17B10OPRM1 | |
| SCHEMBL5777567 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1NPSR1HSD17B10OPRM1 | |
| SCHEMBL12434220 | 0.77 | OPRL1 (0.66) | KDM4EALDH1A1NPSR1HSD17B10OPRM1 | |
| SCHEMBL7053468 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1NPSR1GAACNR2 | |
| SCHEMBL7054560 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1NPSR1GAACNR2 | |
| SCHEMBL7053463 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1NPSR1GAACNR2 | |
| SCHEMBL13563364 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1NPC1GAA | |
| SCHEMBL7254130 | 0.76 | ALDH1A1 (0.48) | KDM4EALDH1A1NPSR1HSD17B10OPRM1 | |
| SCHEMBL12434372 | 0.75 | PARG (0.54) | KDM4EALDH1A1NPSR1HSD17B10OPRM1 | |
| SCHEMBL7057641 | 0.74 | P2RX3 (0.41) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322621-B1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1322621-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6586435-B2 | Useful in treatment of anxiety disorders, affective disorders such as depression, psychosis and schizophrenia, Parkinson's disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-01 | — | — | US | disclosed |
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA) (PL) | 2002-08-01 | — | — | US | disclosed |
| WO-2002024662-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & KO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR1D | KDM4E 4053/4885ALDH1A1 385/4885NPSR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.